Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration

Capivasertib, an AKT inhibitor, interferes with insulin signaling and can induce hyperglycemia. In this case, we monitored blood glucose fluctuations using continuous glucose monitoring (CGM) during capivasertib administration. During the administration period, a post-dose increase in blood glucose was observed, peaking approximately 4 h after oral administration. Additionally, hypoglycemia was detected the following morning, corresponding to approximately 10 h after dinner. These glycemic fluctuations were observed exclusively on dosing days and were completely absent during rest days. The findings highlight the importance of monitoring not only fasting glucose but also post-dose glucose levels for effective glycemic management during capivasertib therapy.